Boston Scientific Begins Patient Enrollment in Clinical Trial Assessing Deep Brain Stimulation for PD
http://www.marketwatch.com/story/bos...k=MW_news_stmp
NATICK, Mass., Nov. 9, 2010 /PRNewswire via COMTEX/ -- Boston Scientific Corporation /quotes/comstock/13*!bsx/quotes/nls/bsx (BSX 6.70, +0.01, +0.15%) today announced the first implantation of its Vercise(TM) Deep Brain Stimulation (DBS) System as part of the VANTAGE clinical trial. VANTAGE is a multi-center, prospective trial designed to examine the improvement of motor function in approximately 40 European patients implanted with the Vercise DBS System for the treatment of Parkinson's disease.